Two targeted drugs in sequence for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial compares two antibody-drug conjugates (targeted cancer-killing drugs) given one after the other to see if they work well for triple-negative breast cancer with low HER2. It aims to provide a new treatment option that may slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and diagnosed with triple-negative breast cancer that has spread (metastatic) or cannot be removed with surgery.
- Your cancer must be 'HER2-low', which means it has a low amount of a protein called HER2 (found by a test).
- Your cancer must have very low or no estrogen and progesterone receptors.
- You must not have been previously treated with certain antibody-drug conjugates like sacituzumab-govitecan or trastuzumab-deruxtecan.
- You must have normal organ function (heart, liver, kidney, blood counts) as checked by blood tests and heart scans.
- You must not have serious, uncontrolled heart disease or a history of lung inflammation (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
This study compares two combinations of drugs for people with a specific type of advanced breast cancer called triple-negative, which is PD-L1 positive. One combination uses sacituzumab govitecan, a targeted drug, with toripalimab, an immunotherapy. The other uses toripalimab with nab-paclitaxel, a chemotherapy. The goal is to see which combination works better.
This study compares two targeted therapies, sacituzumab govitecan and trastuzumab deruxtecan, to see which works better for people with HER2-low or HER2-ultralow metastatic breast cancer. The goal is to find the best treatment order to help control the cancer.
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Hear when a new Neoplasm Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.